Concurrent drug treatment in the five patient groups
| No CAD | CAD-0 Stenosis <50% | CAD-1 Stenosis >50% | CAD-2 Stenosis >50% | CAD-3 Stenosis >50% | p value | |
|---|---|---|---|---|---|---|
| Aspirin | 17/21 (81%) | 24/30 (80%) | 22/26 (85%) | 16/21 (76%) | 22/24 (92%) | 0.448 |
| Nitrates | 9/21 (43%) | 12/30 (40%) | 7/26 (27%) | 7/21 (33%) | 6/24 (25%) | 0.156 |
| Ca antagonists | 4/21 (19%) | 3/30 (10%) | 6/26 (23%) | 4/21 (19%) | 9/24 (38%) | 0.066 |
| β Blockers | 10/21 (48%) | 16/30 (53%) | 17/26 (65%) | 11/21 (52%) | 15/29 (63%) | 0.363 |
| ACE inhibitors | 6/21 (29%) | 4/30 (13%) | 5/26 (19%) | 7/21 (33%) | 4/24 (17%) | 0.967 |
| Diuretics | 2/21 (10%) | 2/30 (7%) | 3/26 (12%) | 2/21 (10%) | 7/24 (29%) | 0.049 |
| Statins | 0/21 (0%) | 5/30 (17%) | 7/26 (27%) | 4/21 (19%) | 6/24 (25%) | 0.044 |
Coronary artery disease classification: CAD-0, vessel alterations but lesion < 50%; CAD-1, lesion > 50% in one vessel; CAD-2, lesion > 50% in two vessels; CAD-3, lesion > 50% in three vessels.
ACE inhibitors, angiotensin converting enzyme inhibitors; Ca antagonists, calcium channel antagonists.